VERA Stock Price, Vera Therapeutics, Inc. Quote, Chart

Market Summary

USD39.68+0.99

Market Closed

2.56%

VERA Alerts

3 major insider sales recently.

VERA Stock Price

View Fullscreen

VERA RSI Chart

VERA Valuation

Market Cap

1.7B

Price/Earnings (Trailing)

-17.65

EV/EBITDA

-17.64

Price/Free Cashflow

-18.37

MarketCap/EBT

-17.65

VERA Price/Earnings (Trailing)

VERA Profitability

Return on Equity

-94.4%

Return on Assets

-54.68%

Free Cashflow Yield

-5.44%

VERA Fundamentals

VERA Earnings

Earnings (TTM)

-96.0M

Earnings Growth (Yr)

20.91%

Earnings Growth (Qtr)

-27.61%

Breaking Down VERA Revenue

Last 7 days

4.4%

Last 30 days

-9.5%

Last 90 days

31.5%

Trailing 12 Months

533.9%

How does VERA drawdown profile look like?

VERA Financial Health

Current Ratio

7.71

Debt/Equity

0.49

Debt/Cashflow

-1.85

VERA Investor Care

Shares Dilution (1Y)

60.73%

Diluted EPS (TTM)

-2.27

Tracking the Latest Insider Buys and Sells of Vera Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 10, 2024	young joseph r	sold	-228,560	40.00	-5,714	svp, finance, chief acct offcr
Apr 03, 2024	grant sean	acquired	1,484,440	14.87	99,828	chief financial officer
Apr 03, 2024	grant sean	sold	-3,954,520	39.6133	-99,828	chief financial officer
Apr 03, 2024	grant sean	sold	-111,016	39.4233	-2,816	chief financial officer
Apr 03, 2024	grant sean	sold	-63,865	39.4232	-1,620	chief financial officer
Apr 03, 2024	grant sean	sold	-13,206	39.4234	-335	chief financial officer
Apr 03, 2024	grant sean	sold	-33,785	39.4234	-857	chief financial officer
Apr 03, 2024	grant sean	sold	-513,331	39.4233	-13,021	chief financial officer
Mar 25, 2024	katabi maha	sold	-13,770,000	40.5	-340,000	-
Mar 22, 2024	katabi maha	sold	-16,748,900	40.51	-413,450	-

Which funds bought or sold VERA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Zurcher Kantonalbank (Zurich Cantonalbank)	unchanged	-	160,615	249,665	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	new	-	143,000	143,000	-%
Apr 25, 2024	Bank of New York Mellon Corp	added	18.39	4,684,090	6,703,760	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-64.79	-1,000	58,000	-%
Apr 23, 2024	HALL LAURIE J TRUSTEE	unchanged	-	17,000	26,000	0.01%
Apr 22, 2024	Raymond James Financial Services Advisors, Inc.	added	7.02	548,535	822,730	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	30,426	280,208	-%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	added	19.48	982,993	1,401,310	-%
Apr 19, 2024	Cutler Group LLC / CA	new	-	57,000	57,000	0.02%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%

Are Funds Buying or Selling VERA?

Are funds buying VERA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VERA

No. of Funds

VERA Alerts

3 major insider sales recently.

Unveiling Vera Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 26, 2024	sofinnova venture partners x, l.p.	5.3%	2,793,987	SC 13D/A
Feb 20, 2024	sofinnova venture partners x, l.p.	6.9%	3,628,446	SC 13D/A
Feb 14, 2024	commodore capital lp	12.3%	5,450,000	SC 13G/A
Feb 14, 2024	commodore capital lp	11.3%	5,001,783	SC 13G/A
Feb 14, 2024	kynam capital management, lp	8.22%	3,650,339	SC 13G/A
Feb 14, 2024	ares trading s.a.	3.6%	1,913,501	SC 13G/A
Feb 14, 2024	citadel advisors llc	0.0%	6	SC 13G/A
Feb 12, 2024	woodline partners lp	2.2%	1,140,632	SC 13G
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 05, 2024	longitude capital partners iv, llc	6.5%	3,429,927	SC 13D/A

Recent SEC filings of Vera Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 12, 2024	4	Insider Trading
Apr 05, 2024	4	Insider Trading
Apr 05, 2024	4	Insider Trading
Apr 04, 2024	ARS	ARS
Apr 03, 2024	144	Notice of Insider Sale Intent
Apr 03, 2024	DEF 14A	DEF 14A
Apr 03, 2024	DEFA14A	DEFA14A
Mar 27, 2024	10-K	Annual Report
Mar 27, 2024	S-8	Employee Benefits Plan
Mar 26, 2024	SC 13D/A	13D - Major Acquisition

Peers (Alternatives to Vera Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Vera Therapeutics, Inc. News

Latest updates

Vera Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet														(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q4
Assets	0.0%	176	176	195	210	131	131	149	165	84.00	91.00	98.00	52.00	55.00	5.00
Current Assets	0.2%	172	172	191	204	126	125	142	158	83.00	90.00	96.00	52.00	54.00	4.00
Cash Equivalents	66.5%	46.00	27.00	34.00	137	43.00	31.00	51.00	112	80.00	86.00	92.00	50.00	54.00	4.00
Net PPE	170.6%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-	1.00
Liabilities	42.3%	74.00	52.00	55.00	52.00	55.00	26.00	27.00	31.00	14.00	6.00	5.00	6.00	4.00	2.00
Current Liabilities	-9.4%	22.00	25.00	27.00	24.00	26.00	16.00	17.00	20.00	8.00	4.00	4.00	4.00	2.00	1.00
Long Term Debt	99.2%	50.00	25.00	25.00	25.00	25.00	5.00	5.00	5.00	5.00	-	-	-	-	-
Shareholder's Equity	-17.8%	102	124	141	158	77.00	106	122	134	70.00	85.00	92.00	-	-	-
Retained Earnings	-9.1%	-309	-283	-263	-243	-213	-180	-155	-141	-124	-107	-99.60	-96.16	-91.45	-38.03
Additional Paid-In Capital	0.8%	410	407	404	401	290	287	278	276	194	193	192	3.00	2.00	1.00
Shares Outstanding	1.4%	43.00	42.00	41.00	38.00	27.00	26.00	26.00	24.00	13.00	21.00	10.00	-	0.00	0.00
Float	-	-	-	449	-	-	-	163	-	-	-	94.00	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Cashflow From Operations	-9.5%	-25,144	-22,973	-17,772	-26,292	-21,162	-18,420	-19,033	-8,981	-6,438	-5,484	-7,665	-4,121	-27,382	-2,447	-2,675	-2,305	-
Share Based Compensation	10.2%	3,221	2,923	2,682	2,667	2,748	2,452	2,025	1,662	962	933	713	404	143	116	11.00	61.00	-
Cashflow From Investing	14.3%	18,556	16,228	-86,449	12,234	13,437	-2,440	-42,094	-39,455	-5,000	-	796	-	57.00	-	-47.00	-52.00	-
Cashflow From Financing	8259.6%	24,828	297	432	107,984	20,709	908	48.00	80,268	4,921	-	48,989	-28.00	79,801	-94.00	616	4,967	-

VERA Income Statement

2023-12-31

Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 78,225	$ 68,993
General and administrative	23,787	21,910
Total operating expenses	102,012	90,903
Loss from operations	(102,012)	(90,903)
Other income (expense):
Interest income	7,979	1,750
Interest expense	(3,786)	(992)
Other income	1,877	1,899
Change in fair value of non-marketable equity securities	(47)	(809)
Total other income	6,023	1,848
Loss before provision for income taxes	(95,989)	(89,055)
Provision for income taxes	(1)	(1)
Net loss	(95,990)	(89,056)
Other comprehensive loss:
Change in unrealized gain (loss) on marketable securities	251	(224)
Comprehensive loss	$ (95,739)	$ (89,280)
Net loss per share attributable to common stockholders, basic	$ (2.25)	$ (3.35)
Net loss per share attributable to common stockholders, diluted	$ (2.25)	$ (3.35)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	42,707,072	26,570,676
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	42,707,072	26,570,676

VERA Balance Sheet

2023-12-31

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 45,681	$ 43,459
Marketable securities	115,035	71,194
Prepaid expenses and other assets, current	11,307	11,045
Total current assets	172,023	125,698
Restricted cash, noncurrent	0	293
Property and equipment, net	92	51
Operating lease right-of-use assets	2,949	5,173
Prepaid expenses and other assets, noncurrent	471	162
Non-marketable equity securities	11	58
Total assets	175,546	131,435
Current liabilities:
Accounts payable	11,118	11,991
Operating lease liabilities	2,436	2,645
Accrued expenses and other liabilities, current	8,749	10,964
Total current liabilities	22,303	25,600
Long-term debt	49,877	24,810
Operating lease liabilities, noncurrent	1,395	3,831
Accrued expenses and other liabilities, noncurrent	286	286
Total liabilities	73,861	54,527
Stockholders' equity
Preferred stock, $0.001 par value; 10,000,000 authorized as of December 31, 2023 and December 31, 2022; no shares issued and outstanding as of December 31, 2023 and December 31, 2022	0	0
Class A common stock, $0.001 par value; 500,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 44,452,161 and 27,800,861 shares issued and outstanding as ofDecember 31, 2023 and December 31, 2022, respectively	44	28
Additional paid-in capital	410,492	290,216
Accumulated other comprehensive gain (loss)	251	(224)
Accumulated deficit	(309,102)	(213,112)
Total stockholders' equity	101,685	76,908
Total liabilities and stockholders' equity	$ 175,546	$ 131,435

About Vera Therapeutics, Inc.

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

CEO	Dr. Marshall Fordyce M.D.
WEBSITE	https://veratx.com
INDUSTRY	Biotechnology
EMPLOYEES	49

Vera Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Vera Therapeutics, Inc.? What does VERA stand for in stocks?

VERA is the stock ticker symbol of Vera Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Vera Therapeutics, Inc. (VERA)?

As of Fri Apr 26 2024, market cap of Vera Therapeutics, Inc. is 1.69 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VERA stock?

You can check VERA's fair value in chart for subscribers.

What is the fair value of VERA stock?

You can check VERA's fair value in chart for subscribers. The fair value of Vera Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Vera Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VERA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Vera Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether VERA is over valued or under valued. Whether Vera Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Vera Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VERA.